Obesity
Novo Nordisk Unveils Enhanced Cardiovascular Benefits of Semaglutide in Post-Hoc Analysis
Semaglutide, Cardiovascular Outcomes, Obesity, Type 2 Diabetes, Novo Nordisk, Post-Hoc Analysis
Eli Lilly Launches Direct-to-Consumer Sales of Zepbound for Weight Loss
Eli Lilly, Zepbound, weight loss medication, direct-to-consumer sales, affordable pricing, obesity treatment
Lilly’s Tirzepatide Demonstrates Significant Reduction in Diabetes Risk and Sustained Weight Loss in Overweight Adults
tirzepatide, diabetes risk reduction, sustained weight loss, overweight adults, pre-diabetes, obesity, Eli Lilly, Mounjaro, Zepbound
Arrowhead Shifts Focus to Obesity Development After Heart Disease Drug Clearance
Arrowhead, obesity development, heart disease drug, biotech, pharmaceuticals, clinical-stage candidates, preclinical assets
Novo Nordisk’s Wegovy Approved in China: Implications and Future Challenges
Novo Nordisk, Wegovy, semaglutide, obesity treatment, China approval, generic competition, patent expiration, pharmaceutical market
Amgen’s Horizon Acquisition Fuels Revenue Growth and Advances Obesity Drug MariTide
Amgen, Horizon Therapeutics, MariTide, obesity drug, revenue growth, pharmaceutical acquisition
Roche Accelerates Obesity Drug Development and Explores M&A Opportunities
Roche, obesity drugs, M&A, pharmaceuticals, drug development
Lilly’s Tirzepatide Clears Phase III Cardiovascular Study on Heels of Novo Nordisk’s Semaglutide
Tirzepatide, Lilly, Phase III, Cardiovascular Study, Novo Nordisk, Semaglutide, Heart Failure, Obesity, Weight Loss
Viking Therapeutics Accelerates Obesity Drug Development to Phase 3 Trials
Viking Therapeutics, Obesity Drug, Phase 3 Trials, GLP-1/GIP Receptor Agonist, VK2735, Weight Loss, Market Competition
Novo Nordisk’s Wegovy Receives UK Approval to Reduce Cardiovascular Risks in Overweight and Obese Adults
Wegovy, Novo Nordisk, UK approval, cardiovascular risks, weight loss, obesity, GLP-1 receptor agonist, semaglutide